The main objective of this guidance is to provide scientific advice on public health principles and considerations for infection and prevention control of COVID-19 in migrant and refugee reception and detention centres in the European Union and European Economic Area (EU/EEA) and the United Kingdom (UK).
This report presents the findings of a survey conducted by ECDC across EU/EEA countries that assessed the level of implementation of IIS and their functionalities, as well as the challenges encountered during the design and implementation.
The Annual Epidemiological Report 2014 gives an overview of the epidemiology of communicable diseases of public health significance in Europe, drawn from surveillance information on the 52 communicable diseases and health issues for which surveillance is mandatory in the European Union and European Economic Area countries.
This report presents the epidemiological situation for emerging and vector-borne diseases as of 2012 and describes the statistical and epidemiological methods used.
This report of the EFSA and ECDC presents the results of zoonoses monitoring activities carried out in 2019 in 36 European countries (28 Member States (MS) and eight non-MS).
This document is intended for hospital staff that use HelicsWin.Net to collect or administer data collected using ECDC’s HAI-Net surveillance of healthcare-associated infections methods (HAINet PPS and ICU).
Helping parents to understand vaccination and supporting their choice to get their children protected is one of the most important aspects of the work of a primary healthcare professional.
In the closed cabin environment of modern airplanes, passengers are frequently exposed to various infectious diseases. This report looks at 12 infectious diseases and, by systematically evaluating literature on on-board transmission, attempts to assess the risk of infection via air circulation in airplanes.
These guidelines are complemented by operational guidelines in relation to tuberculosis, new emerging airborne diseases (e.g. SARS) and meningococcal infections.
This Rapid Risk Assessment assesses the risk posed by the circulation of the Delta variant of SARS-CoV-2 between 1 December 2021 to 31 January 2022, based on modelling scenarios and projected levels of vaccination coverage.